|1.||Cassels, Bruce K: 3 articles (05/2013 - 02/2006)|
|2.||Sparatore, Fabio: 2 articles (02/2013 - 12/2005)|
|3.||Gotti, Cecilia: 2 articles (02/2013 - 12/2005)|
|4.||Clementi, Francesco: 2 articles (02/2013 - 12/2005)|
|5.||Tutka, Piotr: 2 articles (01/2013 - 12/2006)|
|6.||Beyer, Jochen: 2 articles (03/2009 - 05/2007)|
|7.||Maurer, Hans H: 2 articles (03/2009 - 05/2007)|
|8.||Cole, Adam: 1 article (07/2015)|
|9.||Patel, Sanjeevkumar: 1 article (07/2015)|
|10.||Mulhall, Aaron: 1 article (07/2015)|
|1.||Tobacco Use Disorder (Nicotine Dependence)
08/14/2006 - "Cytisine has been used to treat tobacco dependence for 40 years in Eastern Europe. "
05/01/2010 - "Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence."
01/01/2012 - "In Poland, the drugs of first choice in the treatment of nicotine dependence are nicotine replacement therapies (nicotine gum and patches that contain nicotine) and bupropion SR. Quite a popular drugs to help in the fight against addiction are also cytisine and varenicline. "
03/01/2011 - "Nicotine, varenicline, and cytisine are pharmacotherapies for tobacco dependence; the extent to which their in vivo effects vary as a function of differences in nicotinic acetylcholine receptor agonism is not clear. "
|2.||Parkinson Disease (Parkinson's Disease)
|4.||Schizophrenia (Dementia Praecox)
06/23/2000 - "In the present study, using [(3)H]cytisine as a radioligand, we observed a significant 30% decrease in post-mortem striatum of patients with schizophrenia (n=12) as compared to controls (n=12). "
07/01/2001 - "In the same brain region also a significantly higher [3H]cytisine binding (48-77%) was observed in nearly all layers, except for layer I of the schizophrenia subjects, when compared to normal individuals with a history of tobacco use. "
10/01/1999 - "Neuronal nicotinic receptors have been implicated in schizophrenia on the basis of the high incidence of tobacco smoking in patients, abnormalities in cytisine and alpha-bungarotoxin (alphaBGT) binding in the hippocampus, and linkage between auditory P50 deficits and the region of chromosome 15 coding the alpha7 subunit. "
07/01/2001 - "The laminar cortical distribution of the [125I]alpha-bungarotoxin, [3H]cytisine and [3H]epibatidine nicotinic acetylcholine receptor ligands was investigated by quantitative autoradiography in autopsy tissue from the cingulate, orbitofrontal and temporal cortices of control and schizophrenia subjects matched for age and smoking history. "
12/01/2005 - "The present study investigated the effect of the novel cytisine dimer 1,2-bisN-cytisinylethane (CC4) on nAChR natively expressed by SH-SY5Y neuroblastoma cells in culture. "
04/17/1999 - "The pharmacological profile for drug competition toward I-Bgt binding to these recombinant alpha7-nAChR matches that of human native alpha7-nAChR naturally expressed in SH-SY5Y human neuroblastoma cells (rank order potency methyllycaconitine>1, 1-dimethyl-4-phenylpiperazinium>(-)nicotine>cytisine>carbamylch oli ne> /=d-tubocurarine). "
08/22/1994 - "Pharmacological characteristics of native neuronal nicotinic acetylcholine receptor-mediated ion currents in mouse N1E-115 neuroblastoma cells have been investigated by superfusion of voltage clamped cells with known concentrations of the agonists acetylcholine, nicotine and cytisine, and the antagonists alpha-bungarotoxin and neuronal bungarotoxin. "
|4.||5a,6,9,10- tetrahydro- 7H,11H- 8,10a- methanopyrido(2',3'- 5,6)pyrano(2,3- d)azepine
|5.||nicotinic receptor alpha4beta2
|7.||Nicotinic Receptors (Nicotinic Acetylcholine Receptor)
|1.||Drug Therapy (Chemotherapy)